gemcitabine + nab-paclitaxel

DRUG7 trials

Conditions

Borderline Resectable Pancreatic CancerColorectal CancerG12D Mutated KRASMetastatic Pancreatic CarcinomaNon Small Cell Lung CancerPancreatic CancerPancreatic Cancer, AdultPancreatic Ductal Adenocarcinoma

Phase 1

Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

TerminatedNCT02672917

BioNTech Research & Development, Inc.Pancreatic Cancer

Start: 2016-01-31End: 2025-01-14Updated: 2025-01-28

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

RecruitingNCT05431270

Phanes TherapeuticsNon Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2022-08-11End: 2028-08-31Target: 40Updated: 2025-01-31

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

RecruitingNCT07020221

Verastem, Inc.Colorectal Cancer, G12D Mutated KRAS, Non Small Cell Lung Cancer +2

Start: 2025-06-24End: 2028-12-01Target: 295Updated: 2026-04-03

Phase 2

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

NCT02717091

Nagoya UniversityBorderline Resectable Pancreatic Cancer

Start: 2015-07-31End: 2023-06-30Target: 50Updated: 2020-09-10

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

NCT04089150

Australasian Gastro-Intestinal Trials GroupPancreatic Cancer

Start: 2019-10-01End: 2023-08-30Target: 120Updated: 2021-10-22

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients

RecruitingNCT06770452

Zhejiang UniversityMetastatic Pancreatic Carcinoma

Start: 2025-03-25End: 2028-02-01Target: 32Updated: 2025-09-23

Phase 3

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

Not yet recruitingNCT07436741

Tianjin Medical University Cancer Institute and HospitalPancreatic Cancer, Adult

Start: 2026-02-01End: 2030-03-01Target: 106Updated: 2026-02-27

Cancer Research2026-04-03

Abstract PR007: Anti-tumor efficacy of the selective oral KRAS G12D dual ON/OFF inhibitor VS-7375 as a single agent and in combination with targeted agents

Cancer Research2026-03-05

Abstract A076: VS-7375: An oral, selective KRAS G12D dual ON/OFF inhibitor with superior anti-tumor efficacy relative to ON-only KRAS inhibitors

Molecular Cancer Therapeutics2025-10-22

BNT321, a novel monoclonal antibody targeting sialyl Lewis A: Phase 1 monotherapy and combination with mFOLFIRINOX in patients with advanced CA19-9 expressing cancers.

Journal of Clinical Oncology2024-01-201 citations

Quad-shot-immunotherapy: quad-shot radiotherapy with pembrolizumab for advanced/recurrent head and neck cancer

Future Oncology2023-05-185 citations

779 A phase I, dose escalation and expansion study of PT199, a next generation CD73 monoclonal antibody, administered alone and in combination with a PD-1 Inhibitor in adult patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-011 citations

HuMab-5B1 (MVT-5873), a mAb targeting sLe<sup>a</sup>, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Journal of Clinical Oncology2018-05-206 citations

Single agent HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLe<sup>a</sup>, in patients with pancreatic cancer and other CA19-9 positive malignancies.

Journal of Clinical Oncology2017-05-204 citations

Abstract A73: Antitumor activity of MVT-5873, a monoclonal antibody targeting sialyl Lewisa, alone and in combination with gemcitabine/nab-paclitaxel in a BxPC3 human pancreatic cancer xenograft model

Cancer Research2016-12-144 citations

gemcitabine + nab-paclitaxel

Sponsors

Conditions

Phase 1

Phase 2

Phase 3

Related Papers